Comparative Pharmacology
Head-to-head clinical analysis: DENTIPATCH versus PARACAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENTIPATCH versus PARACAINE.
DENTIPATCH vs PARACAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic agent that inhibits sodium ion influx into nerve cells, blocking nerve conduction and pain sensation.
Local anesthetic that reversibly blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction.
Apply one 10 mg/10 cm² transdermal patch to intact skin once daily, typically in the morning; remove after 24 hours and replace with a new patch.
10-20 mg orally every 4-6 hours as needed; maximum 80 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 hours; clinically, steady-state is achieved after 2–3 days of daily application.
Clinical Note
moderateProparacaine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate."
Clinical Note
moderateProparacaine + Clemastine
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine."
Clinical Note
moderateProparacaine + Venlafaxine
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine."
Clinical Note
moderate2.5 hours; prolonged to 8 hours in cirrhosis due to reduced hepatic metabolism
Approximately 60% of the dose is excreted renally as unchanged drug and metabolites; the remainder is eliminated via biliary/fecal routes.
Renal: 90% (70% unchanged, 20% as paracainol glucuronide); Biliary/Fecal: 10%
Category C
Category C
Local Anesthetic
Local Anesthetic
Proparacaine + Nefazodone
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Nefazodone."